Pfizer has raised its full-year 2025 adjusted earnings forecast after posting stronger-than-expected second-quarter results and making significant progress on cost-cutting. The pharmaceutical giant now anticipates earnings of $2.90 to $3.10 per share, up from its previous estimate of $2.80 to $3. It also reaffirmed its full-year revenue forecast of $61 billion to $64 billion.
Waters Corp (WAT.N) raised the lower end of its full-year profit forecast on Monday, following stronger-than-expected second-quarter results fueled by rising demand from biotech firms for its laboratory tools used in drug development and research.
05 Aug 2025-16:33
04 Aug 2025-15:21
